A Diagnostics & Image Week

AutoGenomics (Carlsbad, California) reported that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering (IPO) of shares of its common stock. The number of shares of common stock to be offered, all of which are expected to be offered by AutoGenomics, and the price range for the offering, have not yet been determined.

J.P. Morgan Securities is sole book-running manager of the offering, and Deutsche Bank Securities is co-lead manager. Pacific Growth Equities and Robert W. Baird & Co. are co-managers.

A registration statement relating to these securities has been filed with the SEC, but has not yet become effective.

These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

AutoGenomics said it has developed the first automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics.